Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $1.0 million.

  • Eton Pharmaceuticals' Depreciation & Amortization (CF) rose 26294.96% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 20304.66%. This contributed to the annual value of $1.1 million for FY2024, which is 2719.2% up from last year.
  • Eton Pharmaceuticals' Depreciation & Amortization (CF) amounted to $1.0 million in Q3 2025, which was up 26294.96% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $1.2 million during Q2 2022, and its lowest value of $85000.0 during Q2 2021.
  • Over the past 5 years, Eton Pharmaceuticals' median Depreciation & Amortization (CF) value was $234000.0 (recorded in 2024), while the average stood at $384736.8.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 127764.71% in 2022, then crashed by 8531.17% in 2023.
  • Over the past 5 years, Eton Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $137000.0 in 2021, then soared by 83.94% to $252000.0 in 2022, then grew by 28.97% to $325000.0 in 2023, then increased by 9.23% to $355000.0 in 2024, then skyrocketed by 184.23% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $1.0 million for Q2 2025, and $1.0 million during Q1 2025.